FDA approves asciminib for Philadelphia chromosome-positive chronic myeloid leukemia

[FDA]

On October 29, 2021, the Food and Drug Administration granted accelerated approval to asciminib (Scemblix, Novartis AG) for patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs).


Baca selengkapnya di : http://www.fda.gov...